Stock Taper 
Fulgent Genetics provides comprehensive COVID-19, molecular, and genetic testing services—including oncology, carrier screening, and genome analysis—for healthcare providers, patients, and institutions worldwide.
Fulgent's non-invasive prenatal test (NIPT) screens for various fetal genetic conditions from a maternal blood sample, marking its strategic expansion into the comprehensive prenatal testing market.
Fulgent Genetics, Inc. reported third-quarter 2025 earnings of $0.14 per share, significantly beating the Zacks Consensus Estimate of a loss of $0.24 per share. The company also posted revenues of $84.07 million, surpassing analyst expectations. Following the strong performance, Fulgent raised its full-year 2025 revenue guidance to $325 million and improved its non-GAAP EPS guidance from a loss to a positive $0.30 per share.
In a significant move to broaden its diagnostic offerings, Fulgent Genetics entered into a definitive agreement to acquire selected assets of Bako Diagnostics and the entirety of StrataDx. This acquisition marks Fulgent's strategic entry into the anatomic pathology market, adding specialized dermatopathology and podiatric pathology services to its portfolio.
Corient Private Wealth LP cut its stake in Fulgent Genetics, Inc. (NASDAQ: FLGT) by 34.8% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 45,394 shares of the company's stock after selling 24,261 shares during the period. Corient Private Wealth
Overall rating: C+
| PEER | PRICE | |
|---|---|---|
 CDNA | $69.69 | COMPARE |
 BFLY | $9.07 | COMPARE |
 PSNL | $16.39 | COMPARE |
 CSTL | $35.59 | COMPARE |
 PACB | $2.79 | COMPARE |
 VALN | $5.80 | COMPARE |
 ARVN | $7.41 | COMPARE |
 MYGN | $4.43 | COMPARE |
